Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16
- 22 May 2008
- journal article
- Published by Springer Nature in Leukemia
- Vol. 22 (8) , 1519-1528
- https://doi.org/10.1038/leu.2008.118
Abstract
Insertional activation of cellular proto-oncogenes by replication-defective retroviral vectors can trigger clonal dominance and leukemogenesis in animal models and clinical trials. Here, we addressed the leukemogenic potential of vectors expressing interleukin-2 receptor common -chain (IL2RG), the coding sequence required for correction of X-linked severe combined immunodeficiency. Similar to conventional -retroviral vectors, self-inactivating (SIN) vectors with strong internal enhancers also triggered profound clonal imbalance, yet with a characteristic insertion preference for a window located downstream of the transcriptional start site. Controls including lentivirally transduced cells revealed that ectopic IL2RG expression was not sufficient to trigger leukemia. After serial bone marrow transplantation involving 106 C57Bl6/J mice monitored for up to 18 months, we observed leukemic progression of six distinct clones harboring -retroviral long terminal repeat (LTR) or SIN vector insertions in Evi1 or Prdm16, two functionally related genes. Three leukemic clones had single vector integrations, and identical clones manifested with a remarkably similar latency and phenotype in independent recipients. We conclude that upregulation of Evi1 or Prdm16 was sufficient to initiate a leukemogenic cascade with consistent intrinsic dynamics. Our study also shows that insertional mutagenesis is required for leukemia induction by IL2RG vectors, a risk to be addressed by improved vector design.Keywords
This publication has 56 references indexed in Scilit:
- Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapyJournal of Clinical Investigation, 2007
- Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivoJournal of Clinical Investigation, 2007
- Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapyJournal of Clinical Investigation, 2007
- Gene therapy for severe combined immunodeficiency: are we there yet?Journal of Clinical Investigation, 2007
- The oncogene and developmental regulator EVI1: Expression, biochemical properties, and biological functionsGene, 2007
- Retroviral vector insertion sites associated with dominant hematopoietic clones mark “stemness” pathwaysBlood, 2006
- Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicityBlood, 2006
- Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapyProceedings of the National Academy of Sciences, 2006
- Therapeutic gene causing lymphomaNature, 2006
- RTCGD: retroviral tagged cancer gene databaseNucleic Acids Research, 2004